552 related articles for article (PubMed ID: 15743035)
1. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components.
Tsanou E; Ioachim E; Briasoulis E; Charchanti A; Damala K; Karavasilis V; Pavlidis N; Agnantis NJ
J Exp Clin Cancer Res; 2004 Dec; 23(4):641-50. PubMed ID: 15743035
[TBL] [Abstract][Full Text] [Related]
2. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
[TBL] [Abstract][Full Text] [Related]
3. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
[TBL] [Abstract][Full Text] [Related]
4. Gene expression and protein deposition of major basement membrane components and TGF-beta 1 in human breast cancer.
Nerlich AG; Wiest I; Wagner E; Sauer U; Schleicher ED
Anticancer Res; 1997; 17(6D):4443-9. PubMed ID: 9494547
[TBL] [Abstract][Full Text] [Related]
5. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma.
Mukunyadzi P; Liu K; Hanna EY; Suen JY; Fan CY
Mod Pathol; 2003 Aug; 16(8):796-801. PubMed ID: 12920224
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer.
Götte M; Kersting C; Ruggiero M; Tio J; Tulusan AH; Kiesel L; Wülfing P
Anticancer Res; 2006; 26(1B):621-7. PubMed ID: 16739330
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
9. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma.
Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Salmas M; Malamou-Mitsi V
BJU Int; 2005 Mar; 95(4):655-9. PubMed ID: 15705098
[TBL] [Abstract][Full Text] [Related]
10. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes.
Inki P; Larjava H; Haapasalmi K; Miettinen HM; Grenman R; Jalkanen M
Eur J Cell Biol; 1994 Feb; 63(1):43-51. PubMed ID: 8005104
[TBL] [Abstract][Full Text] [Related]
11. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
12. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
Joensuu H; Anttonen A; Eriksson M; Mäkitaro R; Alfthan H; Kinnula V; Leppä S
Cancer Res; 2002 Sep; 62(18):5210-7. PubMed ID: 12234986
[TBL] [Abstract][Full Text] [Related]
13. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
14. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
15. Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma.
Kurokawa H; Zhang M; Matsumoto S; Yamashita Y; Tanaka T; Takamori K; Igawa K; Yoshida M; Fukuyama H; Takahashi T; Sakoda S
J Oral Pathol Med; 2006 May; 35(5):301-6. PubMed ID: 16630294
[TBL] [Abstract][Full Text] [Related]
16. Association of syndecan-1 with angiogenesis-related markers, extracellular matrix components, and clinicopathological features in colorectal carcinoma.
Mitselou A; Skoufi U; Tsimogiannis KE; Briasoulis E; Vougiouklakis T; Arvanitis D; Ioachim E
Anticancer Res; 2012 Sep; 32(9):3977-85. PubMed ID: 22993347
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of syndecan-1 expression in breast cancer.
Leivonen M; Lundin J; Nordling S; von Boguslawski K; Haglund C
Oncology; 2004; 67(1):11-8. PubMed ID: 15459490
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of syndecan-1 in prostate cancer.
Kiviniemi J; Kallajoki M; Kujala I; Matikainen MT; Alanen K; Jalkanen M; Salmivirta M
APMIS; 2004 Feb; 112(2):89-97. PubMed ID: 15056224
[TBL] [Abstract][Full Text] [Related]
19. [Loss of fragile histidine triad expression and metastasis in breast cancer].
Zhao P; Li XY; Chen LZ
Ai Zheng; 2002 Jun; 21(6):668-70. PubMed ID: 12452072
[TBL] [Abstract][Full Text] [Related]
20. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis.
Maeda T; Desouky J; Friedl A
Oncogene; 2006 Mar; 25(9):1408-12. PubMed ID: 16247452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
